| Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine FP Polack, SJ Thomas, N Kitchin, J Absalon, A Gurtman, S Lockhart, ... New England journal of medicine 383 (27), 2603-2615, 2020 | 13133 | 2020 |
| Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months SJ Thomas, ED Moreira Jr, N Kitchin, J Absalon, A Gurtman, S Lockhart, ... New England Journal of Medicine 385 (19), 1761-1773, 2021 | 1136 | 2021 |
| Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents RW Frenck Jr, NP Klein, N Kitchin, A Gurtman, J Absalon, S Lockhart, ... New England Journal of Medicine 385 (3), 239-250, 2021 | 892 | 2021 |
| Vaccine protection against Zika virus from Brazil RA Larocca, P Abbink, JPS Peron, PM de A. Zanotto, MJ Iampietro, ... Nature 536 (7617), 474-478, 2016 | 578 | 2016 |
| Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys P Abbink, RA Larocca, RA De La Barrera, CA Bricault, ET Moseley, ... Science 353 (6304), 1129-1132, 2016 | 525 | 2016 |
| A recombinant vesicular stomatitis virus Ebola vaccine JA Regules, JH Beigel, KM Paolino, J Voell, AR Castellano, Z Hu, ... New England Journal of Medicine 376 (4), 330-341, 2017 | 423 | 2017 |
| Serotype-specific differences in the risk of dengue hemorrhagic fever: an analysis of data collected in Bangkok, Thailand from 1994 to 2006 JR Fried, RV Gibbons, S Kalayanarooj, SJ Thomas, A Srikiatkhachorn, ... PLoS neglected tropical diseases 4 (3), e617, 2010 | 376 | 2010 |
| Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial K Modjarrad, CC Roberts, KT Mills, AR Castellano, K Paolino, ... The Lancet Infectious Diseases 19 (9), 1013-1022, 2019 | 296 | 2019 |
| Natural history of plasma leakage in dengue hemorrhagic fever: a serial ultrasonographic study A Srikiatkhachorn, A Krautrachue, W Ratanaprakarn, L Wongtapradit, ... The Pediatric infectious disease journal 26 (4), 283-290, 2007 | 279 | 2007 |
| Determinants of inapparent and symptomatic dengue infection in a prospective study of primary school children in Kamphaeng Phet, Thailand TP Endy, KB Anderson, A Nisalak, IK Yoon, S Green, AL Rothman, ... PLoS neglected tropical diseases 5 (3), e975, 2011 | 264 | 2011 |
| A review of Dengvaxia®: development to deployment SJ Thomas, IK Yoon Human vaccines & immunotherapeutics 15 (10), 2295-2314, 2019 | 257 | 2019 |
| D-dimer correlates with proinflammatory cytokine levels and outcomes in critically ill patients AF Shorr, SJ Thomas, SA Alkins, TM Fitzpatrick, GS Ling Chest 121 (4), 1262-1268, 2002 | 243 | 2002 |
| Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in … K Ramsauer, M Schwameis, C Firbas, M Müllner, RJ Putnak, SJ Thomas, ... The Lancet infectious diseases 15 (5), 519-527, 2015 | 240 | 2015 |
| Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: How alterations in assay conditions impact performance SJ Thomas, A Nisalak, KB Anderson, DH Libraty, S Kalayanarooj, ... The American journal of tropical medicine and hygiene 81 (5), 825, 2009 | 229 | 2009 |
| Reconstruction of antibody dynamics and infection histories to evaluate dengue risk H Salje, DAT Cummings, I Rodriguez-Barraquer, LC Katzelnick, J Lessler, ... Nature 557 (7707), 719-723, 2018 | 199 | 2018 |
| Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo … K Modjarrad, L Lin, SL George, KE Stephenson, KH Eckels, ... The Lancet 391 (10120), 563-571, 2018 | 186 | 2018 |
| Dengue and other common causes of acute febrile illness in Asia: an active surveillance study in children MR Capeding, MN Chua, SR Hadinegoro, IIHM Hussain, R Nallusamy, ... PLoS neglected tropical diseases 7 (7), e2331, 2013 | 173 | 2013 |
| Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults W Sun, D Cunningham, SS Wasserman, J Perry, JR Putnak, KH Eckels, ... Human vaccines 5 (1), 33-40, 2009 | 165 | 2009 |
| Revealing the microscale spatial signature of dengue transmission and immunity in an urban population H Salje, J Lessler, TP Endy, FC Curriero, RV Gibbons, A Nisalak, ... Proceedings of the National Academy of Sciences 109 (24), 9535-9538, 2012 | 162 | 2012 |
| Intracellular cytokine production by dengue virus–specific T cells correlates with subclinical secondary infection S Hatch, TP Endy, S Thomas, A Mathew, J Potts, P Pazoles, DH Libraty, ... Journal of Infectious Diseases 203 (9), 1282-1291, 2011 | 162 | 2011 |
